The national drug alliance procurement office has issued a notification detailing the tendering rules for the 9th national Volume-Based Procurement (VBP) round, along with the finalized drug list. This round involves a total of 42 drugs, spanning 12 treatment areas and representing a market value of RMB 10.963 billion (USD 1.5 billion). Notably, two drugs initially on the shortlist\u2014Baxter\u2019s esmolol and Pfizer\u2019s dexrazoxane\u2014will not participate. All related filings are required to be submitted in Shanghai on November 6, with the tender taking place on the same day.<\/p>\n\n\n\n
Manufacturer Standards and Consortium Formation<\/strong>
The rules outline standards for manufacturers, stating that different companies filing the same drug variety under certain conditions will be considered as one filing manufacturer. These conditions include having the same person in charge, a direct controlling or management relationship, confirmation of a subordinate relationship by the China Medical Statistics Annual Report, or a valid registration approval transfer. Enterprises can form a consortium to make a joint filing, with the lowest “unit comparable price” determining the valid filing in cases of multiple consortia.<\/p>\n\n\n\n